Correspondence in reference to previously published manuscript: “Faouzi Djebbari et al. Efficacy and infection morbidity of front‐line immuno‐chemotherapy in follicular lymphoma. Eur J Haematol 2020; 105: 667–671.”

Rituximab and cyclophosphamide-containing regimens (cyclophosphamide, vincristine, prednisone with or without doxorubicin) had been predominantly used as standard immunochemotherapy for symptomatic indolent B-cell lymphomas (i-BCLs) until the recent introduction of bendamustine plus rituximab schedule1 . However, the increased incidence of opportunistic infections following bendamustine exposure have raised questions regarding its safety and widespread adoption2 .